Previous 10 | Next 10 |
2023-03-09 16:58:50 ET Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): FY GAAP EPS of -$0.11. As of December 31, 2022, Merrimack had cash and cash equivalents of $19.4 million, compared to $14.2 million as of December 31, 2021 For further details see: M...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022. “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen in Novembe...
Summary In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share. After adjusting for NOLs, tax inte...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss rights plan (the “ Plan ”) that wa...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billi...
Palm Beach, FL – November 10, 2022 – FinancialNewsMedia.com News Commentary – The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market competition, the market participants are implementing methods including increased ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: rafapress / Shutterstock.com Upstart (NASDAQ: UPST ) stock is sliding lower on Wednesday following a poor performance in the third quarter of 2022 and a weak outlook. Let’s start with that out...
MACK Stock Explodes 240%+ Overnight, Here Are 3 Penny Stocks To Watch Now Thanks to the 2022 stock market crash, there are plenty of penny stocks to watch. The broad market sell-off has taken even some of the most popular names and sent them below the $5 mark. That might be bad for ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Champhei Merrimack Pharmaceuticals (NASDAQ: MACK ) stock is rocketing higher on Wednesday following positive clinical trial data . Ipsen , Merrimack Pharmaceuticals’ partner, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! We’ve got earnings reports, a public o...
News, Short Squeeze, Breakout and More Instantly...
Merrimack Pharmaceuticals Inc. Company Name:
MACK Stock Symbol:
NASDAQ Market:
2024-05-12 12:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidat...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at...